NAMS vs. VKTX
NAMS (NewAmsterdam Pharma Company N.V.) and VKTX (Viking Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, NAMS returned 34.98%/yr vs 30.87%/yr for VKTX. Their 0.25 correlation means their historical movements had little consistent relationship.
Performance
NAMS vs. VKTX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NAMS achieves a -20.78% return, which is significantly lower than VKTX's -9.78% return.
NAMS
- 1D
- -2.35%
- 1M
- -20.21%
- 6M
- -10.70%
- YTD
- -20.78%
- 1Y
- 30.59%
- 3Y*
- 34.98%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 28.59%
VKTX
- 1D
- -4.14%
- 1M
- -15.22%
- 6M
- 9.30%
- YTD
- -9.78%
- 1Y
- -2.88%
- 3Y*
- 30.87%
- 5Y*
- 38.85%
- 10Y*
- 36.63%
- ALL TIME*
- 12.42%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $31.87M | $30.03M | $43.19M | |
| $78.34M | $82.45M | $79.18M |
NAMS vs. VKTX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
NAMS NewAmsterdam Pharma Company N.V. | -20.78% | 36.50% | 130.08% | 2.48% | -0.91% |
VKTX Viking Therapeutics, Inc. | -9.78% | -12.57% | 116.23% | 97.98% | 131.53% |
Correlation
The correlation between NAMS and VKTX is 0.50, which is moderate. They have sometimes moved together and sometimes differently, sharing some price drivers without tracking each other closely.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.50 |
Correlation (3Y) Balances recent behavior with more history. | 0.31 |
Correlation (All Time) Calculated using the full available price history since Nov 23, 2022 | 0.25 |
Over the past year, NAMS and VKTX have become more correlated (0.50) than their long-term average of 0.25, meaning their price movements have been converging.
Fundamentals
NAMS:
$3.25B
VKTX:
$3.70B
NAMS:
-$2.11
VKTX:
-$4.67
NAMS:
$22.57M
VKTX:
$0.00
NAMS:
$19.47M
VKTX:
-$208.00K
NAMS:
-$173.45M
VKTX:
-$539.16M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NAMS vs. VKTX — Risk / Return Rank
NAMS
VKTX
NAMS vs. VKTX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for NewAmsterdam Pharma Company N.V. (NAMS) and Viking Therapeutics, Inc. (VKTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NAMS | VKTX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.51 | ||
| Sortino ratioReturn per unit of downside risk | +0.60 | ||
| Omega ratioGain probability vs. loss probability | 1.12 | 1.08 | +0.05 |
| Calmar ratioReturn relative to maximum drawdown | 0.84 | -0.06 | +0.89 |
| Martin ratioReturn relative to average drawdown | 1.57 | -0.11 | +1.68 |
Loading charts...
Drawdowns
NAMS vs. VKTX - Drawdown Comparison
The maximum NAMS drawdown since its inception was -66.23%, smaller than the maximum VKTX drawdown of -90.41%. Use the drawdown chart below to compare losses from any high point for NAMS and VKTX.
Loading charts...
Drawdown Indicators
| NAMS | VKTX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -66.23% | -90.41% | +24.18% |
Max Drawdown (1Y)Largest decline over 1 year | -32.96% | -45.14% | +12.18% |
Max Drawdown (3Y)Largest decline over 3 years | -46.08% | -78.86% | +32.78% |
Max Drawdown (5Y)Largest decline over 5 years | — | -78.86% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -89.26% | — |
Current DrawdownCurrent decline from peak | -32.96% | -66.41% | +33.45% |
Average DrawdownAverage peak-to-trough decline | -22.14% | -60.03% | +37.89% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.54% | 23.55% | -6.01% |
Volatility
NAMS vs. VKTX - Volatility Comparison
NewAmsterdam Pharma Company N.V. (NAMS) has a higher volatility of 17.78% compared to Viking Therapeutics, Inc. (VKTX) at 16.06%. This indicates that NAMS's price experiences larger fluctuations and is considered to be riskier than VKTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NAMS | VKTX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.78% | 16.06% | +1.72% |
Volatility (6M)Calculated over the trailing 6-month period | 40.50% | 41.26% | -0.76% |
Volatility (1Y)Calculated over the trailing 1-year period | 57.94% | 74.46% | -16.52% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 70.81% | 101.84% | -31.03% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 70.81% | 97.12% | -26.31% |
Dividends
NAMS vs. VKTX - Dividend Comparison
Neither NAMS nor VKTX has paid dividends to shareholders.
Financials
NAMS vs. VKTX - Financials Comparison
This section allows you to compare key financial metrics between NewAmsterdam Pharma Company N.V. and Viking Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
NAMS and VKTX have a correlation of 0.50, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NAMS has higher volatility (17.78%) compared to VKTX (16.06%). In terms of maximum drawdown, NAMS dropped -66.23% vs VKTX's -90.41%.
NAMS currently has the higher Sharpe Ratio (0.48 vs -0.03), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NAMS and VKTX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer